Literature DB >> 24687562

Evaluation of time, attendance of medical staff and resources for radiotherapy in pediatric and adolescent patients. The DEGRO-QUIRO trial.

Angelika Zabel-du Bois1, Stefanie Milker-Zabel, Frank Bruns, Hans Christiansen, Iris Ernst, Normann Willich, Wolfgang Popp, Jürgen Debus, Horst Sack.   

Abstract

BACKGROUND: The German Society of Radiation Oncology (DEGRO) initiated a multicenter trial to develop and evaluate adequate modules to assert core procedures in radiotherapy. The aim of this prospective evaluation was to methodical assess the required resources for radiotherapy in pediatric and adolescent patients.
MATERIAL AND METHODS: At three radiotherapy centers of excellence (University Hospitals of Heidelberg and Münster, the Medical School of Hannover), the manpower and time required for radiotherapy in pediatric and adolescent patients was prospectively documented consistently over a 2-year period. The data were collected using specifically developed standard forms and were evaluated using specific process analysis tools.
RESULTS: A total number of 1914 data sets were documented and carefully analyzed. The personnel time requirements for all occupational groups were calculated as total time needed for a specific procedure and mean time per person. Regarding radiotherapy in general anesthesia, the required manpower was higher. The personnel time requirements in these cases were also longer, mainly due to longer room occupancy. Overall, the required resources were remarkably similar between the three different departments and may, therefore, be considered as representative.
CONCLUSION: For the first time, the personnel time requirements of a radiotherapy department for the maintenance, protection, and optimization of operational readiness for radiotherapy in pediatric and adolescent patients with and without general anesthesia were determined methodically.

Entities:  

Mesh:

Year:  2014        PMID: 24687562     DOI: 10.1007/s00066-014-0619-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  16 in total

1.  Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources.

Authors:  R Esco; A Palacios; J Pardo; A Biete; J A Carceller; C Veiras; G Vazquez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

2.  Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer.

Authors:  J C Horiot; K A Johansson; D G Gonzalez; E van der Schueren; W van den Bogaert; G Notter
Journal:  Radiother Oncol       Date:  1986-08       Impact factor: 6.280

Review 3.  The cost of radiation therapy.

Authors:  Nicolas Paul Ploquin; Peter Brian Dunscombe
Journal:  Radiother Oncol       Date:  2008-01-30       Impact factor: 6.280

4.  [Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery : QUIRO-DEGRO Trial].

Authors:  A Zabel-du Bois; S Milker-Zabel; M Henzel; W Popp; J Debus; H Sack; R Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2012-08-01       Impact factor: 3.621

5.  Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial.

Authors:  E Blank; N Willich; R Fietkau; W Popp; J Schaller-Steiner; H Sack; F Wenz
Journal:  Strahlenther Onkol       Date:  2012-01-14       Impact factor: 3.621

6.  Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial.

Authors:  R Fietkau; W Budach; N Zamboglou; H-J Thiel; H Sack; W Popp
Journal:  Strahlenther Onkol       Date:  2011-12-24       Impact factor: 3.621

7.  Anesthesia for pediatric external beam radiation therapy.

Authors:  J T Fortney; E C Halperin; C M Hertz; S R Schulman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

Review 8.  Wilms tumour: prognostic factors, staging, therapy and late effects.

Authors:  Sue C Kaste; Jeffrey S Dome; Paul S Babyn; Norbert M Graf; Paul Grundy; Jan Godzinski; Gill A Levitt; Helen Jenkinson
Journal:  Pediatr Radiol       Date:  2007-11-17

9.  Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.

Authors:  J Bernier; J C Horiot; H Bartelink; K A Johansson; L Cionini; D Gonzalèz Gonzalèz; H Hamers; W van den Bogaert
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

10.  Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET).

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

View more
  4 in total

1.  Hepatotoxicity after liver irradiation in children and adolescents : results from the RiSK.

Authors:  Pascal Rösler; Hans Christiansen; Rolf-Dieter Kortmann; Carmen Martini; Christiane Matuschek; Frank Meyer; Christian Rübe; Thorsten Langer; Raphael Koch; Hans Theodor Eich; Normann Willich; Diana Steinmann
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

2.  Radiotherapy infrastructure and human resources in Switzerland : Present status and projected computations for 2020.

Authors:  Niloy Ranjan Datta; Shaka Khan; Dietmar Marder; Daniel Zwahlen; Stephan Bodis
Journal:  Strahlenther Onkol       Date:  2016-07-25       Impact factor: 3.621

3.  Evaluation of the time required for overhead tasks performed by physicians, medical physicists, and technicians in radiation oncology institutions: the DEGRO-QUIRO study.

Authors:  Cornelia Sack; Horst Sack; Normann Willich; Wolfgang Popp
Journal:  Strahlenther Onkol       Date:  2014-09-23       Impact factor: 3.621

4.  Accurate method for evaluating the duration of the entire radiotherapy process.

Authors:  Chenlei Guo; Peng Huang; Yexiong Li; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2020-07-25       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.